In addition, the first-in-class SUMO inhibitor, TAK-981, demonstrated immune-modulating properties.101,102 Considering that MYC mediates complex cross-talk between tumour cells and the tumour microenvironment,103,104 SUMO inhibitors should also be tested in autochthonous immune-proficient models. The gene discussed is MYC; the disease is neoplasm.